Article Text

Download PDFPDF
Randomised controlled trial
Fentanyl Pectin Nasal Spray reduces breakthrough cancer pain intensity compared with placebo in people taking at least 60 mg daily oral morphine or equivalent
  1. Carol P Curtiss
  1. Tufts University Medical School, Boston, Massachusetts, USA
  1. Correspondence to Carol P Curtiss
    Master of Science in Pain Research, Education and Policy (MSPREP) Program, 73 James Street, Greenfield, MA 01301, USA; carol. curtiss{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science

Implications for nursing practice

  • Breakthrough pain is a significant problem for people with cancer.

  • Patterns of breakthrough pain are often different from the pharmacokinetics of immediate release oral analgesics.

  • Matching patterns of breakthrough pain with medications that work within the timeframe of breakthrough pain may improve breakthrough pain management.

  • A comprehensive assessment includes evaluating breakthrough pain separately from persistent pain, using similar strategies for screening and assessing both types of pain.

  • Fentanyl Pectin Nasal Spray (FPNS) provides an additional option to manage breakthrough cancer pain (BTCP).

  • Patient education regarding the correct use of medications for persistent and breakthrough pain and the appropriate use of novel routes of administration is important for optimal analgesic medication efficacy and safety.

Implications for research

  • Additional research on assessing and managing breakthrough pain is important to identify appropriate treatment options.

  • Novel routes of medication administration for breakthrough pain may …

View Full Text


  • Competing interests CPC is on the Advisory Board and Speakers Bureau for Meda Pharmaceuticals.